Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.69 and traded as high as $0.83. Brainstorm Cell Therapeutics shares last traded at $0.8295, with a volume of 32,971 shares trading hands.
Brainstorm Cell Therapeutics Price Performance
The stock has a market capitalization of $9.15 million, a price-to-earnings ratio of -0.25 and a beta of 0.30. The firm’s fifty day moving average is $0.77 and its 200-day moving average is $0.69.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
